Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Editorial Board
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • ascls.org
    • ascls.org

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society for Clinical Laboratory Science
  • ascls.org
    • ascls.org
  • My alerts
  • Log in
  • My Cart
American Society for Clinical Laboratory Science

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Editorial Board
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • Follow ASCLS on Twitter
  • Visit ASCLS on Facebook
  • Follow ASCLS on Instagram
  • RSS Feed
Review_ArticleReview Article

Emicizumab and the clinical laboratory

Michael A Nardi
American Society for Clinical Laboratory Science August 2020, ascls.119.002204; DOI: https://doi.org/10.29074/ascls.119.002204
Michael A Nardi
New York University School of Medicien
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

  1. Michael A Nardi1
  1. New York University School of Medicien
  1. ↵* Corresponding author; email: michael.nardi{at}nyumc.org

Abstract

Abstract This review describes and discusses the different assays used to measure the effectiveness of the novel therapeutic agent, emicizumab, as well as monitor factor VIII activity in patients with hemophilia A. Emicizumab is a humanized, asymmetric, bispecific, IgG4 monoclonal antibody designed to mimic the function of activated factor VIII. Clinical studies have demonstrated its utility in the successful treatment of hemophilia A patients with and without anti-factor VIII alloantibodies. The conventional methods currently used for monitoring management of hemophilia A will be discussed along with why they may be inappropriate for patients receiving emicizumab. Alternative methods, i.e global testing, will be presented and discussed in the context of emicizumab. With the increasing availability of treatment with emicizumab it is important the clinical laboratory understands the mechanism, interaction with conventional coagulation assays, and alternative methods for its monitoring.

  • Chemistry
  • Hematology
  • Hemostasis
  • Received December 17, 2019.
  • Revision received March 6, 2020.
  • Accepted April 30, 2020.
  • Published by American Society for Clinical Laboratory Science
PreviousNext
Back to top

In this issue

American Society for Clinical Laboratory Science: 30 (4)
American Society for Clinical Laboratory Science
Vol. 30, Issue 4
Fall 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Society for Clinical Laboratory Science.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Emicizumab and the clinical laboratory
(Your Name) has sent you a message from American Society for Clinical Laboratory Science
(Your Name) thought you would like to see the American Society for Clinical Laboratory Science web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Emicizumab and the clinical laboratory
Michael A Nardi
American Society for Clinical Laboratory Science Aug 2020, ascls.119.002204; DOI: 10.29074/ascls.119.002204

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Save to my folders
Share
Emicizumab and the clinical laboratory
Michael A Nardi
American Society for Clinical Laboratory Science Aug 2020, ascls.119.002204; DOI: 10.29074/ascls.119.002204
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Review Article

  • Pathophysiology of Thrombotic Thrombocytopenia Purpura
  • Laboratory findings in hematology, clinical chemistry, and urinalysis for patients with thrombotic thrombocytopenic purpura
  • An Overview of the Laboratory's Role in the Diagnosis and Treatment of Thrombotic Thrombocytopenic Purpura
Show more Review Article

Clinical Practice

  • Innovative Approach to Moderating Risk of Nosocomial Infection During Anesthesia
  • The impact of blood utilization guidelines on product usage
Show more Clinical Practice

Similar Articles

Keywords

  • Chemistry
  • Hematology
  • Hemostasis

© 2022 The American Society for Clinical Laboratory Science

Powered by HighWire